Eli Lilly bets $100M on gene-silencing technology

Oct 29, 2018

Eli Lilly is spending $100 million for a stake in Cambridge-based Dicerna Pharmaceuticals as part of a licensing deal to gain access to the biotech's gene-silencing technology.

The companies expect to collaborate on developing more than 10 experimental drugs to treat pain, neuro-degenerative diseases and cardio-metabolic disorders, utilizing Dicerna's proprietary GalXC™ RNAi technology platform to progress new drug targets toward clinical development and commercialization.

For the use of Dicerna’s GalXC gene-silencing platform, Lilly will pay the company $100 million upfront and buy a $100 million equity stake at a per share price of $18.47.

Gene-silencing, which is attracting the attention of numerous drugmakers, works by targeting and silencing specific genetic material and blocking the production of disease-causing proteins.

Read the press release

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments